CTC enumeration and characterization has predictive and prognostic implications in patients with metastatic breast cancer treated with exemestane plus the mTOR inhibitor everolimus

被引：0
|
作者：
Agelaki, Sofia [1 ,2 ]
Mavroudis, Dimitris [1 ,2 ]
Spiliotaki, Maria [2 ]
Politaki, Eleni [2 ]
Papadaki, Maria A. [2 ]
Apostolaki, Stella [2 ]
Nikolaou, Christos [1 ]
Georgoulias, Vassilis [1 ,2 ]
机构：
[1] Univ Hosp Heraklion, Iraklion, Greece
[2] Univ Crete, Sch Med, Lab Tumor Cell Biol, Rethimnon, Greece
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-01-13
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Clinical, biological and histological features predictive of response to everolimus in metastatic breast cancer patients
    Van den Bossche, V.
    Jadot, G.
    Augusto, D.
    Samartzi, V.
    Castela, S.
    Lejeune, S.
    Seront, E.
    ANNALS OF ONCOLOGY, 2019, 30 : 59 - +
  • [42] Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC
    Nakatsukasa, Katsuhiko
    Niikura, Naoki
    Kashiwabara, Kosuke
    Amemiya, Takeshi
    Watanabe, Ken-ichi
    Hata, Hironobu
    Kikawa, Yuichiro
    Taniike, Naoki
    Yamanaka, Takashi
    Mitsunaga, Sachiyo
    Nakagami, Kazuhiko
    Adachi, Moriyasu
    Kondo, Naoto
    Shibuya, Yasuyuki
    Hayashi, Naoki
    Naito, Mariko
    Yamashita, Toshinari
    Umeda, Masahiro
    Mukai, Hirofumi
    Ota, Yoshihide
    BMC CANCER, 2021, 21 (01)
  • [43] Efficacy of everolimus and exemestane for the treatment of metastatic hormone receptor-positive breast cancer in patients previously treated with CDK4/6 inhibitors
    Mo, Hanjie
    Renna, Catherine E.
    Moore, Halle C. F.
    Abraham, Jame
    Kruse, Megan L.
    Montero, Alberto J.
    LeGrand, Susan B.
    Budd, G. Thomas
    CANCER RESEARCH, 2021, 81 (04)
  • [44] Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC
    Katsuhiko Nakatsukasa
    Naoki Niikura
    Kosuke Kashiwabara
    Takeshi Amemiya
    Ken-ichi Watanabe
    Hironobu Hata
    Yuichiro Kikawa
    Naoki Taniike
    Takashi Yamanaka
    Sachiyo Mitsunaga
    Kazuhiko Nakagami
    Moriyasu Adachi
    Naoto Kondo
    Yasuyuki Shibuya
    Naoki Hayashi
    Mariko Naito
    Toshinari Yamashita
    Masahiro Umeda
    Hirofumi Mukai
    Yoshihide Ota
    BMC Cancer, 21
  • [45] A COST-UTILITY ANALYSIS OF EVEROLIMUS PLUS EXEMESTANE FOR THE TREATMENT OF ER+HER2-METASTATIC BREAST CANCER IN THE UNITED KINGDOM
    Taylor, M.
    Lewis, L.
    Vieira, J.
    Chandiwana, D.
    VALUE IN HEALTH, 2013, 16 (07) : A416 - A416
  • [46] PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane
    Dinja T. Kruger
    Mark Opdam
    Vincent van der Noort
    Joyce Sanders
    Michiel Nieuwenhuis
    Bart de Valk
    Karin J. Beelen
    Sabine C. Linn
    Epie Boven
    Journal of Cancer Research and Clinical Oncology, 2020, 146 : 3013 - 3023
  • [47] PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane
    Kruger, Dinja T.
    Opdam, Mark
    van der Noort, Vincent
    Sanders, Joyce
    Nieuwenhuis, Michiel
    de Valk, Bart
    Beelen, Karin J.
    Linn, Sabine C.
    Boven, Epie
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (11) : 3013 - 3023
  • [48] Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial
    Zanudo, Jorge Gomez Tejeda
    Barroso-Sousa, Romualdo
    Jain, Esha
    Jin, Qingchun
    Li, Tianyu
    Buendia-Buendia, Jorge E.
    Pereslete, Alyssa
    Abravanel, Daniel L.
    Ferreira, Arlindo R.
    Wrabel, Eileen
    Helvie, Karla
    Hughes, Melissa E.
    Partridge, Ann H.
    Overmoyer, Beth
    Lin, Nancy U.
    Tayob, Nabihah
    Tolaney, Sara M.
    Wagle, Nikhil
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [49] Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial
    Jorge Gómez Tejeda Zañudo
    Romualdo Barroso-Sousa
    Esha Jain
    Qingchun Jin
    Tianyu Li
    Jorge E. Buendia-Buendia
    Alyssa Pereslete
    Daniel L. Abravanel
    Arlindo R. Ferreira
    Eileen Wrabel
    Karla Helvie
    Melissa E. Hughes
    Ann H. Partridge
    Beth Overmoyer
    Nancy U. Lin
    Nabihah Tayob
    Sara M. Tolaney
    Nikhil Wagle
    Nature Communications, 15
  • [50] Renal failure requiring hemodialysis in two patients with metastatic breast cancer treated with everolimus
    Kuo, James C.
    Gorddard, Nicole
    Stuart-Harris, Robin
    BREAST CANCER MANAGEMENT, 2015, 4 (03) : 129 - 134
12345